>>clearly vendors of the reference drugs are going to have less pricing leverage with payers than they did before FoBs arrived.
Agreed. But a lot depends on just how tough the insurers/PBMs want to play. Their extreme position could be that they would only pay for the biosimilar.
Market Data 
Markets 
AI
